| Document |
Document Title |
|
JPH10511645A |
Compositions and method for the minimization or prevention of adhesion formation, whereby an effective amount of at least one lazaroid compound, preferably one of general formula I, is administered for a period of time sufficient to perm...
|
|
JP2812397B2 |
New 9 alpha -hydroxy-17-methylene steroids are prepared by the introduction of a substituted 17-methylene group in 9 alpha -hydroxyandrost-4-ene-3,17-dione. The resulting compounds are useful starting compounds in the synthesis of cortic...
|
|
JPH10510813A |
Novel cationic amphiphiles are provided that facilitate transport of biologically active (therapeutic) molecules into cells. The amphiphiles contain lipophilic groups derived from steroids, from mono or dialkylamines, or from alkyl or ac...
|
|
JP2807144B2 |
A cholesteric liquid crystal compound having the following general formula (I), and a polymric cholesteric liquid crystal compound formd by polymerization thereof and a polymer dispersed liquid crystal display device having an improved c...
|
|
JPH10509958A |
PCT No. PCT/FR95/01595 Sec. 371 Date Jun. 4, 1997 Sec. 102(e) Date Jun. 4, 1997 PCT Filed Dec. 4, 1995 PCT Pub. No. WO96/17823 PCT Pub. Date Jun. 13, 1996Cationic lipids of general formula (I), wherein m is an integer from 2 to 6 inclusi...
|
|
JPH10509692A |
The invention relates to novel, androstane steroids which are the ligand semiochemicals which bind to neuroepithelial receptors. The steroids are useful as ligands to neuroepithelial receptors in the human vomeronasal gland to stimulate ...
|
|
JPH10509458A |
Methods, compositions, and compounds for modulating the GABAA receptor-chloride ionophore complex to alleviate stress, anxiety, seizures, mood disorders, PMS and PND and to induce anesthesia.
|
|
JPH10509423A |
The invention relates to estrene steroids, which bind to neuroepithelial cells in the human vomeronasal organ. The steroids are preferably administered in the form of a pharmaceutical composition containing one or more pharmaceutically a...
|
|
JP2792876B2 |
PCT No. PCT/DE88/00447 Sec. 371 Date Jan. 16, 1990 Sec. 102(e) Date Jan. 16, 1990 PCT Filed Jul. 15, 1988 PCT Pub. No. WO89/00578 PCT Pub. Date Jan. 26, 1989.New 11 beta phenyl-4,9,15-estratrienes of formula I (I) are described, where X ...
|
|
JP2794297B2 |
Products of formula (I): in which: R1 = optionally substituted carbocyclic or heterocyclic aryl or aralkyl radical, R2 = in position alpha or beta = hydrocarbon radical of 1 to 18 carbon atoms, X = -(CH2)n- with n = 1, 2 or 4 or X = -CH=...
|
|
JP2785023B2 |
Novel 19-nor steroids of the formula I wherein R' is selected from the group consisting of propyl, propenyl, iodoethenyl, iodoethynyl or -C 3BOND C-CH2-Hal1, Hal1 is selected from the group consisting of fluorine, chlorine and bromine an...
|
|
JP2785017B2 |
Products of the formula in which R1 = C1-18 organic radical R2 = CH3 or C2H5 A and B Re = H, C1-6 Alk or acyl R3 or R4 denote: one optionally protected or acylated OH or alkoxy and the other optionally substituted aryl, R5: optionally su...
|
|
JP2783560B2 |
The invention relates to androstane-17-carboxylic acid esters, represented by general formula (I): wherein R1 represents a lower alkyl group containing 1 to 4 carbon atoms, a lower alkyl group containing 2 to 4 carbon atoms substituted b...
|
|
JP2784846B2 |
Inhibitors of sex steroid activity, for example those having the general structure may be used as part of a pharmaceutical composition to provide antiestrogenic effects and/or to suppress estrogen synthesis. Such pharmaceutical compositi...
|
|
JPH10507451A |
A process of providing novel compounds of Formula (I), that are useful as 6-azaandrostenone testosterone 5-alpha-reductase inhibitors, from commercially available compounds of Formula (II) +TR wherein the substituents are as defined in t...
|
|
JPH10507176A |
The disclosed invention is a process for preparing 17-beta-substituted-androsta-3,5-dien-3-carboxylic acids from 3-halo-17-beta-substituted-androsta-3,5-dienes. The process may be performed in either of two ways: (1) the 3-halo compound ...
|
|
JP2768864B2 |
PURPOSE: To obtain a new amine compd. as an intermediate of an amine steroid useful in the treatment of medulla spinalis injury, head injury, subarachnoid hemorrhage, asthma, muscular dystrophy, skin graft rejection, septic shock, etc. C...
|
|
JP2768707B2 |
The invention relates to new 11-arylsteroid compounds, having a strong antiprogestin and a weak or nonexistent antiglucocorticoid activity, to processes for preparing said compounds and also to pharmaceutical preparations which contain t...
|
|
JP2760870B2 |
PCT No. PCT/EP89/01090 Sec. 371 Date Mar. 20, 1991 Sec. 102(e) Date Mar. 20, 1991 PCT Filed Sep. 20, 1989 PCT Pub. No. WO90/03385 PCT Pub. Date Apr. 5, 1990.New 11 beta -phenyl-14 beta H-steroids of general formula (I), where Z is an oxy...
|
|
JPH10147593A |
To simply produce the subject compound useful as a synthetic intermediate, etc., for medicines by reacting a specific 3-hydroxysteroid derivative with phthalimide and then reacting the resultant compound with hydrazine hydrate or phenylh...
|
|
JP2753562B2 |
PURPOSE: To obtain the subject derivative useful in treatment, etc., of benign or malign diseases of genitals, etc., which is a novel 11-benzaldoxime-estra-diene derivative and has a good progesterone inhibitory effect and an anti- gluco...
|
|
JP2746041B2 |
PURPOSE: To obtain the subject derivative for therapeutic agent, etc., for bone metabolic diseases such as osteoporosis, consisting of a steroid derivative containing a phosphoric acid group and capable of making a steroid compound to ac...
|
|
JP2742331B2 |
Compounds of the general formula (1> wherein X represents the residue of the A, B and C rings of a steroid, R represents a hydrogen atom or an alkyl group of 1 to 4 carbon atoms, R<14> represents a hydrogen atom a halogen atom or an alky...
|
|
JP2736169B2 |
Polymorph "A" a novel polymorphic form of N-t-butyl-androst-3,5-diene-17 beta -carboxamide-3-carboxylic acid. Novel processes for preparing polymorph "A" are also disclosed.
|
|
JPH1081625A |
To obtain a medicinal composition useful for treatment of prostatic adenocarcinoma by containing a depressant compound for steroid 5-α-reductase and a medicinally permissible carrier. As a compound of steroid 5-α-reductase inhibitor, 1...
|
|
JP2729320B2 |
19-Substituted progesterone derivatives and related compounds which are active as 19-hydroxylase inhibitors and useful as antihypertensive agents are described herein. The compounds are prepared using appropriate synthetic pathways which...
|
|
JP2727127B2 |
|
|
JP2727466B2 |
19-Fluoro- and cyano- substituted 21-hydroxyprogesterone derivatives and related compounds which are active as 19-hydroxylase inhibitors and useful as antihypertensive agents are described herein. The compounds are prepared using appropr...
|
|
JPH10502648A |
The invention relates to novel chelate formers containing sulphonamide groups and their metallic chelates of general formula (I) in which n, m, p, V<1>, V<2>, V<3>, V<4>, X<1>, X<2>, X<3>, R<1>, R<2>, R<3> and R<4> have different meaning...
|
|
JP2718834B2 |
|
|
JP2717792B2 |
Novel 19-nor-steroids of the formula (I) wherein the A ring is either Re is selected from the group consisting of hydrogen, acyl and optionally substituted alkyl of 1 to 6 carbon atoms, R is methyl or ethyl, R1 is selected from the group...
|
|
JP2710789B2 |
|
|
JP2711672B2 |
This invention is directed to 17 beta -(cyclopropylamino)androst-5-en-3 beta -ol and related compounds and also to a method for using such compounds in the treatment of androgen-dependent disorders. The compounds are prepared by the hydr...
|
|
JPH10501233A |
Invented are 17 alpha and 17 beta -substituted aromatic A ring steroidal synthetic compounds, pharmaceutical compositions containing these compounds, and methods for using these compounds to inhibit steroid 5- alpha -reductase.
|
|
JPH10500946A |
17 beta -Cyano-3,17 alpha -dihydroxy-6-methylandrosta-3,5,9(11)-triene 3-ethyl ether (II) is prepared by reacting 3-hydroxy-6-methylandrosta-3,5,9(11)-trien-17-one 3- ethyl ether (I) with hydrogen cyanide at a pH of about 7 to about 11. ...
|
|
JP2702280B2 |
Invented is a Method of Treating Prostatic Adenocarcinoma by employing asteroid 5- alpha -reductase inhibiting compound or a combination of steroid 5- alpha -reductase inhibiting compounds.
|
|
JPH1017474A |
To prepare a therapeutic agent effective in treating psoriasis by including a taurine conjugate of ursodeoxychloric acid as an active ingredient therein. This therapeutic agent for psoriasis comprises a trauroursodeoxychloric acid of the...
|
|
JP2696672B2 |
11-Benzaldoxime-oestradiene derivatives of the general formula I and their pharmaceutically acceptable salts, a process for their preparation and pharmaceutical compositions containing them are described. The described compounds display ...
|
|
JPH09328498A |
To stereoselectively obtain the subject compound useful as a raw material for vitamin D3, etc., by reacting cyclochol-22-ene-24-aldehyde with nitromethane in the presence of a Ln binuclear catalyst, converting the nitro group into an est...
|
|
JPH09512547A |
The invention discloses 3-ketosteroids of the following formula used to inhibit steroid C17-20 lyase: wherein R is OH, C1-C6 alkanoyl, C1-C6 alkanoyloxy, C1-C4 alkanol, COCH2OH, CO2H, CONR7R8, cyclopropyloxy, cyclopropylamino, acetylthio...
|
|
JPH09512270A |
The present invention relates to methods and compositions for the transformation of cells. In particular, compositions and methods are disclosed which include combinations of the nucleic acid of interest and polyhydroxylated or polyglyco...
|
|
JPH09315979A |
To prepare a cholagogic agent, comprising a 7-N-acetylglycosamine conjugate of ursodeoxycholic acid, tauroursodeoxycholic acid or glycoursodeoxycholic acid, excellent in water solubility and having promoting actions on bile secretion. Th...
|
|
JP2687209B2 |
A novel steroid of the formula I wherein X is methylene and R is an optionally substituted carbocyclic aryl or heterocyclic aryl or optionally substituted vinyl or ethynyl or X is a simple bond or -S- and R is optionally substituted carb...
|
|
JP2684180B2 |
PCT No. PCT/FR87/00096 Sec. 371 Date Nov. 25, 1987 Sec. 102(e) Date Nov. 25, 1987 PCT Filed Mar. 26, 1987 PCT Pub. No. WO87/05908 PCT Pub. Date Oct. 8, 1987. (I) (II) (III) (IV) (V) (VI) Products having the formula (I) wherein R1 is an a...
|
|
JPH09511486A |
Libraries of synthetic receptors are disclosed. The receptors include a polyfunctional organic template which is covalently linked to two or more oligomers. The oligomers may be the same or different and may be straight chain, cyclic or ...
|
|
JP2677626B2 |
The invention relates to new 17-hydroxy androsta-1,4-diene-3-one derivatives of the following formula wherein each of R and R3, independently, is hydrogen or C1-C6 alkyl; R1 is hydrogen, halogen or C1-C6 alkyl; R2 is hydrogen or C1-C6 al...
|
|
JP2675418B2 |
Compounds of formula (I) in which X<1>, X<2> and X<3> are hydrogen, halogen, CF3, C1-6alkyl, OH, C1-6alkoxy, CN, NO2, N(R<1>)2, CHO or CO2R<1>; A is O or S, n is 0 or 1, R<1> is H or C1-8alkyl and R<3> is alpha -H, alpha -OH, or alpha -a...
|
|
JP2674957B2 |
PURPOSE: To analyze an objective compound for analysis, capable of performing a high level judgment, at a high sensitivity, safely at a low cost and also in a wide application range by using a labeled compound emitting an electromagnetic...
|
|
JP2675436B2 |
Invented are 3-acetic acid-steroidal compounds, pharmaceutical compositions containing the compounds, and methods of using these compounds to inhibit steroid 5 alpha -reductase including using these compounds to reduce prostate size and ...
|
|
JP2667418B2 |
PCT No. PCT/FR87/00244 Sec. 371 Date Feb. 24, 1988 Sec. 102(e) Date Feb. 24, 1988 PCT Filed Jun. 24, 1987 PCT Pub. No. WO88/00202 PCT Pub. Date Jan. 14, 1988.Compounds obtained from the associative synthesis of sulfur-containing or sulfu...
|
